Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Isis designates ISIS-AATRx candidate in collaboration with GSK

Isis Pharmaceuticals, Inc. announced today that it has designated the second development candidate, ISIS-AATRx, in its collaboration with GlaxoSmithKline

12 Oct 2011

Progenra, Ono enter ubiquitin pathway research collaboration

Progenra, Inc. announced today that it has entered into a research collaboration with Ono Pharmaceutical Co., Ltd. Under the agreement, Progenra will collaborate with Ono to conduct assay development and high throughput screening by using Progenra's proprietary technology on multiple targets in the ubiquitin pathway.

11 Oct 2011

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

11 Oct 2011

Nexcelom to distribute FCS Express 4 Cytometry Software

De Novo Software, a leading provider of flow and image cytometry data analysis solutions, and Nexcelom Bioscience, a leading supplier of cell counting and analysis products for bioresearch and drug discovery, announced today a licensing agreement enabling Nexcelom to distribute De Novo Software's flagship product, FCS Express 4 Software.

11 Oct 2011

CRT, Cancer Research UK establish group of scientists with expertise in lipid metabolism

Cancer Research Technology, Cancer Research UK's commercial arm, has established a group of scientists with expertise in lipid metabolism - getting energy from fats and making building blocks for cell growth - to develop targets for potential new cancer drugs.

4 Oct 2011

Complete Genomics, Scripps collaborate to unlock genetic secrets of lifelong health

Complete Genomics Inc., the whole human genome sequencing company, and the not-for-profit Scripps Health system today announced a major collaboration that will help further the Wellderly Study, a landmark scientific research initiative aimed at unlocking the genetic secrets of lifelong health.

4 Oct 2011

Researchers apply new approach to take a close look at amyloid plaque formation

Researchers at the University of Toronto Scarborough (UTSC) and Osaka University applied a new approach to take a close look at amyloid plaque formation, a process that plays important roles in Alzheimer's disease.

4 Oct 2011

AMRI announces final results from ALB-127158(a) Phase I clinical studies on obesity

AMRI announced today the final results from its Phase I clinical studies on its novel MCH1 receptor antagonist, ALB-127158(a) during the 29th Annual Scientific Meeting of the Obesity Society in Orlando, Fla.

4 Oct 2011

Novel drug shows promise for MLL leukemia

According to British scientists a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia (MLL). MLL is the most common form of leukemia in babies. The study appeared in the journal Nature where scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151.

3 Oct 2011

Potential new drug could treat mixed-lineage leukaemia

A team lead by Cancer Research UK scientists have shown that a potential new drug could treat mixed-lineage leukaemia (MLL), the most common form of leukaemia in babies, according to a study published in Nature today.

3 Oct 2011

Researchers identify protein-based blood biomarkers in patients treated with EPO

Biomarkers in the bloodstream could provide a rapid assessment of therapeutic intervention in ischemic stroke and allow patient stratification

1 Oct 2011

UCSF protein researcher wins NIH's Early Independence Award

James Fraser, PhD, a protein researcher who studies structural biology at the California Institute for Quantitative Biosciences (QB3) at the University of California, San Francisco (UCSF), is one of 10 recipients of a prestigious award for young scientists given for the first time by the National Institutes of Health.

1 Oct 2011

Yale researchers use AB SCIEX's QTRAP technology to synthesize phosphoproteins

AB SCIEX, a global leader in life science analytical technologies, today announced that Yale University researchers used QTRAP technology to prove the validity of a new approach to synthesize phosphoproteins.

28 Sep 2011

Isis files patent infringement lawsuit against Santaris for antisense drugs

Isis Pharmaceuticals, Inc. announced today it has filed a patent infringement lawsuit against Santaris Pharma A/S and Santaris Pharma A/S Corp. in the United States District Court of the Southern District of California.

26 Sep 2011

Nuevolution announces collaboration in drug discovery with Boehringer Ingelheim

Nuevolution A/S today announced that it has entered into collaboration with Boehringer Ingelheim, using Nuevolution’s proprietary Chemetics® drug discovery technology. Within the framework of the collaboration, hundreds of millions of diverse small molecules will be screened to discover and advance drug candidates against drug targets of interest to Boehringer Ingelheim.

20 Sep 2011

University of Colorado, SuviCa complete license agreement for CU cancer drug screening technology

SuviCa Inc. of Boulder and the University of Colorado recently completed an exclusive license agreement for a CU drug screening technology to identify novel therapies for cancer.

20 Sep 2011

SK Biopharmaceuticals, Mayo Clinic collaborate to develop new treatments for ALS

Mayo Clinic's campus in Florida has entered into a collaborative and sponsored research agreement with SK Biopharmaceuticals of Seoul, South Korea, with the goal of developing new treatments for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. The collaboration marks a new approach to combating a disease that has proved difficult to treat in recent clinical trials.

20 Sep 2011

Revolution in drug discovery underway in West Midlands, UK

A revolution in the drug discovery industry is underway, with universities across the West Midlands leading the effort by working in partnership with industry to focus on improving patient care.

19 Sep 2011

Reducing levels of protein FKBP51 may yield new antidepressant therapies

Decreasing expression of a protein associated with susceptibility to depression made old mice resistant to depressive-like behavior while improving their hormonal response to stress, a study led by researchers at the University of South Florida found. The lack of this protein, FKBP51, did not adversely affect their memory, learning, or basic motor functions.

17 Sep 2011

Nanion’s automated patch clamp platforms show unparalleled results using stem cell derived cardiomyocytes

The Patchliner and the SyncroPatch 96 have successfully been used for compound analysis under current- and voltage clamp recording conditions using different stem cell-derived cardiomyocytes. The exceptional cell-platform-compatibility and the unique experimental possibilities offered by Nanion’s platforms open up whole new avenues for compound safety testing.

16 Sep 2011